Fredun Pharmaceuticals Ltd () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Venus Remedies

Fredun Pharma

Sakar Healthcare

Kwality Pharma

Wanbury

Lincoln Pharma.

NGL Fine Chem

Bajaj Healthcare

Themis Medicare

Accent Microcell

Remus Pharma.

Why is Fredun Pharmaceuticals Ltd ?

Healthy long term growth as Net Sales has grown by an annual rate of 39.73% and Operating profit at 55.03%

With a growth in Net Profit of 127.87%, the company declared Very Positive results in Sep 25

The company has declared positive results for the last 6 consecutive quarters
OPERATING PROFIT TO INTEREST(Q) Highest at 2.89 times
PBT LESS OI(Q) At Rs 13.01 cr has Grown at 71.64%
NET SALES(Q) At Rs 145.30 cr has Grown at 35.35%

With ROCE of 20.2, it has a Attractive valuation with a 3.3 Enterprise value to Capital Employed

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 141.48%, its profits have risen by 63.5% ; the PEG ratio of the company is 0.5

Market Beating Performance

The stock has generated a return of 141.48% in the last 1 year, much higher than market (BSE500) returns of 2.12%

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Fredun Pharma should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Fredun Pharma for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Fredun Pharma

141.48%

3.22

43.88%

Sensex

4.83%

0.41

11.83%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

39.73%

EBIT Growth (5y)

55.03%

EBIT to Interest (avg)

2.55

Debt to EBITDA (avg)

2.89

Net Debt to Equity (avg)

1.03

Sales to Capital Employed (avg)

1.65

Tax Ratio

22.33%

Dividend Payout Ratio

2.11%

Pledged Shares

Institutional Holding

1.61%

ROCE (avg)

14.74%

ROE (avg)

13.09%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

5.62

EV to EBIT

16.19

EV to EBITDA

14.95

EV to Capital Employed

3.28

EV to Sales

1.96

PEG Ratio

0.49

Dividend Yield

0.04%

ROCE (Latest)

20.23%

ROE (Latest)

18.34%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

28What is working for the Company

OPERATING PROFIT TO INTEREST(Q)

Highest at 2.89 times

PBT LESS OI(Q)

At Rs 13.01 cr has Grown at 71.64%

NET SALES(Q)

At Rs 145.30 cr has Grown at 35.35%

PBDIT(Q)

Highest at Rs 22.35 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 15.38%

PAT(Q)

Highest at Rs 9.73 cr.

EPS(Q)

Highest at Rs 20.61

-3What is not working for the Company

INTEREST(9M)

At Rs 22.41 cr has Grown at 57.59%

Loading Valuation Snapshot...

Here's what is working for Fredun Pharma

Profit After Tax (PAT) - Quarterly

At Rs 9.73 cr has Grown at 127.9%

Year on Year (YoY)

MOJO Watch

Near term PAT trend is very positive

PAT (Rs Cr)

Operating Profit to Interest - Quarterly

Highest at 2.89 times

in the last five quarters

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Profit Before Tax less Other Income (PBT) - Quarterly

At Rs 13.01 cr has Grown at 71.64%

Year on Year (YoY)

MOJO Watch

Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Net Sales - Quarterly

At Rs 145.30 cr has Grown at 35.35%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly

Highest at Rs 22.35 cr.

in the last five quarters

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly

Highest at 15.38%

in the last five quarters

MOJO Watch

Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly

Highest at Rs 13.01 cr.

in the last five quarters

MOJO Watch

Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly

Highest at Rs 9.73 cr.

in the last five quarters

MOJO Watch

Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly

Highest at Rs 20.61

in the last five quarters

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Here's what is not working for Fredun Pharma

Interest - Nine Monthly

At Rs 22.41 cr has Grown at 57.59%

over preceding nine months period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)